153 related articles for article (PubMed ID: 8350943)
1. Characterization of lymphokine-activated killer cells from peripheral blood and lymph nodes of non-Hodgkin's lymphoma patients.
Nadkarni JJ; Jhaver KG; De AK; Soman CS; Nadkarni KS
Neoplasma; 1993; 40(1):15-20. PubMed ID: 8350943
[TBL] [Abstract][Full Text] [Related]
2. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
3. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
4. Natural killer activity and NK cytotoxic factors in peripheral blood and lymph node cells from non-Hodgkin's lymphoma patients.
Nadkarni JJ; Mehta BA; Koppikar SB; Soman CS; Shrikhande SS; Advani SH
Neoplasma; 1989; 36(6):701-8. PubMed ID: 2615873
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine activated killer cells and interleukin-2 production in patients with cervical carcinoma.
De AK; Jhaver KG; Kamat MR; Nadkarni JJ
Neoplasma; 1991; 38(5):493-9. PubMed ID: 1835519
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer.
Tatake RJ; Krishnan N; Rao RS; Fakih AR; Gangal SG
Int J Cancer; 1989 Apr; 43(4):560-6. PubMed ID: 2522911
[TBL] [Abstract][Full Text] [Related]
7. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
Morikawa Y; Watanabe S; Kodama T
Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
[TBL] [Abstract][Full Text] [Related]
8. Immunoreactivity of lymphocytes from draining lymph nodes, peripheral blood and tumor infiltrates from oral cancer patients.
Mukhopadhyaya R; Tatake RJ; Krishnan N; Rao RS; Fakih AR; Naik SL; Gangal SG
J Clin Lab Immunol; 1989 Sep; 30(1):21-5. PubMed ID: 2641790
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
10. Natural killer and lymphokine-activated killer cell-mediated cytotoxicity in patients with oral cancer.
Gangal SG; Tatake RJ; Krishnan N; Mukhopadhyaya R; Naik SL; Fakih AR; Rao RS
Semin Surg Oncol; 1989; 5(5):347-50. PubMed ID: 2814145
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
13. [Lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) therapy that improved lymphadenopathy in a patient with B cell non-Hodgkin's lymphoma].
Nakata K; Ogawa R; Wake A; Sato T; Nagata K; Mori N; Tsukada J; Misago M; Zeki K; Morimoto I
Rinsho Ketsueki; 1992 Feb; 33(2):205-10. PubMed ID: 1635170
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
15. [The characteristic of lymphokine-activated killer cells induced from tumor draining lymph-node cell].
Meng YG; Fu CY; Wang YZ
Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):535-7, 574. PubMed ID: 7835130
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients.
Wong PY; Staren ED; Tereshkova N; Braun DP
J Surg Res; 1998 Apr; 76(1):95-103. PubMed ID: 9695747
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of lymphokine-activated killer cell development in young and old healthy humans.
Provinciali M; Di Stefano G; Fabris N
Nat Immun; 1995; 14(3):134-44. PubMed ID: 8832897
[TBL] [Abstract][Full Text] [Related]
19. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
20. [Cytotoxicity of effector cells of the peripheral blood, lymph nodes and spleen in Hodgkin's disease].
Blokhina NG; Bykovskaia SN; Kharabadze MV; Kupriianova TA; Agafonov VA
Biull Eksp Biol Med; 1989 Nov; 108(11):600-3. PubMed ID: 2633827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
